NEW YORK (GenomeWeb) – WaferGen Biosystems reported after the close of the market Monday an 18 percent drop in first quarter revenues, primarily due to weak sales of its SmartChip system, though it saw a sharp increase in SmartChip consumables and services.

For the three-month period ended March 31, WaferGen's revenues slipped to $1.1 million from $1.4 million year over year, well off the average analysts' estimate of $2.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.